Leukemia | 最新测序技术分析儿童B急淋白血病分子亚型及预后结果 儿童急性B淋巴细胞白血病(B-ALL)的分子亚型主要由肿瘤细胞中携带的驱动基因组变异及其驱动下的特征性基因表达来描绘。这些驱动变异也作为重要的预后标志被纳入B-ALL的危险度分级...
( 1982 ) Prognosis of chronic lymphocytic leukemia: a multivariate survival analysis of 150 cases . Blood , 59 , 1001 – 1005 .Rozman C, Montserrat E, Feliu E, et al. Prognosis of chronic lymphocytic leukemia: A multivariate survival analysis of 150 cases. Blood 1982; 59: 1001-5....
Treatment Outcomes for Childhood Leukemia Although the prognosis may differ based on the subtype of childhood leukemia, with current therapies, the 5-year survival rate is approximately 90% for ALL and 68% for AML. For More Information American Cancer Society www.cancer.org/cancer/types/leukemia-i...
Tumor biomarkers for diagnosis, prognosis and targeted therapy Yue Zhou Lei Tao Yinglan Zhao Signal Transduction and Targeted Therapy (2024) Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia? Hagop Kantarjian ...
Limited evidence supports the use of early endpoints to evaluate the success of initial treatment of extranodal NK/T-cell lymphoma (ENKTCL) in the modern era. We aim to analyze progression-free survival at 24 months (PFS24) and subsequent overall surviva
One way that scientists think about cancer is by looking at 5-year survival rates. This is the number of people out of 100 who are still alive 5 years after they find out they have cancer. The 5-year survival rate varies for the different kinds of leukemia: ...
Although the younger age group has improved survival rate, the prognosis in older patients continues to be very poor [4]. 1.1 AML Classification French-American-British (FAB) classification and the newer World Health Organization (WHO) classification are the two of the main systems that have ...
Acute lymphoblastic leukemia (ALL) is a type of blood cancer. Learn more about the causes, risk factors, symptoms, diagnosis, treatment types, and prognosis for acute lymphoblastic leukemia.
mutations was nearly equal within the long-lived subgroup. This mutation type-specific effect on prognosis has been noted before25, but was not sufficient for a full discrimination of our two subgroups. Thus, additional molecular factors are likely to contribute to the observed survival differences....
Furthermore, whereas CD20 expression is often low in BL-ALL, it is expressed by 40–50% of patients with more mature B-lymphoid neoplasms and is associated with poorer prognosis [24, 25]. Specifically, CD20 expression at diagnosis predicts relapse in adult patients, such that CD20-directed ...